SLC5A2 and heart failure: This article focuses on the antioxidative effect of drugs used in heart failure therapy, specifically sodium-glucose co-transporter 2 (SGLT2) inhibitors, which have contributed to positive clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF) with or without diabetes, thereby reducing cardiovascular-related mortality [11,12].